Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Mirum Pharmaceuticals, Inc and Takeda Pharmaceutical Company Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

09/21/2021 | 08:00am EDT

Mirum Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that the companies have entered into an exclusive licensing agreement for the development and commercialization of maralixibat in Japan for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Maralixibat, an investigational, orally administered medication, is being evaluated globally in ALGS, PFIC, and BA. Under the terms of the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan. Takeda will also be responsible for development, including conducting clinical studies in cholestatic indications. Mirum has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome. The NDA is currently under priority review with a PDUFA, or FDA decision date, of September 29, 2021. Mirum also recently submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with ALGS.


© S&P Capital IQ 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
05:29pWAVE LIFE SCIENCES : Takeda Pharmaceutical Partially Amend Central Nervous System Collabor..
MT
04:48pCALITHERA BIOSCIENCES : Buys Two Clinical-Stage Assets from Takeda to Boost Oncology Pipel..
MT
02:39pCalithera Agrees to Acquire 2 Clinical-Stage Assets from Takeda Pharma
DJ
10/14TAKEDA PHARMACEUTICAL : Working With Immusoft to Develop B-Cell Therapies for Rare Neurome..
MT
10/13TR1 : Notification of Major Shareholding
DJ
10/13TAKEDA PHARMACEUTICAL : BioLife Plasma Services Announces Expansion of Plasma Donation Cen..
BU
10/13Immusoft and Takeda Pharmaceutical Company Limited Collaborate to Discover and Develop ..
CI
10/12POSEIDA THERAPEUTICS : Takeda to Jointly Develop Novel Non-Viral In Vivo Gene Therapies
MT
10/12Poseida Therapeutics, Inc. Announces Research Collaboration with Takeda Pharmaceutical ..
CI
10/12Poseida Therapeutics, Takeda Pharmaceutical in Research, License Pact
DJ
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 391 B 29 651 M 29 651 M
Net income 2022 248 B 2 169 M 2 169 M
Net Debt 2022 3 258 B 28 487 M 28 487 M
P/E ratio 2022 20,5x
Yield 2022 5,61%
Capitalization 5 043 B 44 141 M 44 102 M
EV / Sales 2022 2,45x
EV / Sales 2023 2,31x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 207,00 JPY
Average target price 4 487,14 JPY
Spread / Average Target 39,9%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-14.59%44 517
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657